In a report released on March 27, Thomas Smith from Leerink Partners reiterated a Buy rating on Keros Therapeutics (KROS – Research Report), with a price target of $129.00.
Thomas Smith has given his Buy rating due to a combination of factors that underscore Keros Therapeutics’ potential in the market. The recent FDA approval of Winrevair for the treatment of pulmonary arterial hypertension (PAH) serves as an important benchmark for Keros Therapeutics’ own drug, KER-012. This approval not only validates the mechanism of action shared by KER-012 but also sets a regulatory precedent for future treatments in this class. Smith acknowledges that while the approved drug has specific warnings and monitoring requirements, these are not seen as overly burdensome, suggesting that KER-012 could benefit from a similar regulatory approach.
Furthermore, Smith identifies a significant opportunity for KER-012 to differentiate itself in terms of efficacy and safety within the PAH patient population. He notes that there is a subset of patients with connective tissue disease—making up a notable portion of the PAH population—who were underrepresented in Winrevair’s pivotal trials. This gap represents a potential area where KER-012 could demonstrate superior efficacy. The ability for patient self-administration with proper training, as allowed by Winrevair’s label, is also seen as a positive factor for the uptake of similar treatments. Smith’s confidence in Keros Therapeutics is bolstered by these strategic market opportunities and the clear pathway laid out by the FDA’s recent approval.
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Keros Therapeutics (KROS) Company Description:
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company’s protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
